New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
14:11 EDTCBMXCombiMatrix fundamentals, technicals point to breakout, TheStreet says
Shares of CombiMatrix could "double or much more" from their current level given the company's strong fundamentals, position as an attractive takeover target and technical set-up of its stock chart, contends's Roberto Pedone. Reference Link
News For CBMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2014
08:17 EDTCBMXCombiMatrix expects Q3 prenatal tests volume up 71%
CombiMatrix announced that it expects to report record volumes of prenatal testing in the Q3 and nine months ended September 30, 2014. Preliminary growth rates of 71% and 64% are estimated for billable prenatal tests in the Q3 and year-to-date periods, respectively, compared to the comparable periods in 2013. The Company believes the growth rate in prenatal testing, which includes both prenatal and miscarriage testing, is the result of the Company's strategic shift to focus on its prenatal molecular diagnostics testing markets, where the Company believes that chromosomal microarray analysis is becoming the standard of care. Total microarray testing volumes for the Q3 is expected to increase 24% to 1,420 billable tests performed, compared to 1,145 tests performed in the third quarter of 2013. The Company also expects to report record cash receipts for the Q3 and nine months ended September 30, which are expected to be over $2.0M and $5.4M respectively, compared to $1.5M and $4.4M, respectively, in the comparable 2013 periods. Record cash reimbursement can be attributable to increased microarray revenues coupled with increased management focus on reimbursement and collections during the past year. The Company expects to announce complete results for the quarter and conduct a conference call following the completion of its independent auditors' review.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use